April 4, 2018 I We just concluded our annual compilation and analysis of sales of recombinant therapeutic antibodies and proteins for the year 2018. The results show another all time high of global sales of more than US$ 202 mln, a plus of 7.3% compared with the previous year. The main reason is the continuous annual growth of antibody sales. Since 2011, antibody sales grew with an annual growth rate of 14.1% and now make out more than 70% of all biologics sales. On the contrary, sales of classical therapeutic proteins (erythropoietins, interferons, coagulation factors, G-CSF etc) decreased by 7.4% in 2018 in comparison with the previous year, mainly due to biosimilar competition and changes in the treatment paradigm, e.g for multiple sclerosis

While sales of cancer antibodies still are growing fuelled by immuno-oncology antibodies (+54%), anti-inflammatory antibodies contribute to more than 50% of all antibody sales. The decrease of anti-TNF antibody sales is  more than compensated by new anti-inflammatory antibodies

The 13th edition of our annual report about sales of Blockbuster Biologics includes 46 blockbuster biologic therapeutics with 2018 sales exceeding US$ 1 bln: 28 antibodies and 18 proteins. Ten biologics reached global sales in 2018 of more than US$ 5 bln.

The report „Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteinsprovides a compilation of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2018. Sales data were obtained from company publications and refer to branded products originating from companies based in regulated markets. All sales data were converted from their original, reported currency into US$ using official currency exchange rates as of March 28, 2018. Sales figures represent the sum of revenues in all territories where the products are marketed. Growth rates mostly are presented as reported (in some cases on constant exchange rates).

Sales data are presented for each product within the respective class of biologics. The data were analyzed to establish a ranking list of blockbuster biologics with 2018 sales higher than US$ 1 bln. Another ranking list was prepared for the TOP 30 companies according to biologics sales in 2018.